Pharma R&D: Time for a sharp right turn on the road to profitable growth 
Published: Jun-20-13

The challenges facing pharmaceutical companies’ R&D functions have never been greater. Under pressure to deliver innovative products while holding spending flat, organizations are feeling the impact. In fact, in the past three years, 18 R&D locations have closed in the United States—an additional 14 in Europe. But a shift is under way. Leading pharmas are leveraging new information management platforms to reduce costs, shorten drug development timelines, and maintain quality and compliance. These companies are turning to pre-competitive collaboration.

Better, faster outcomes

By working with other research partners, the flexible, pre-competitive collaboration model means companies no longer have to bear all the development burdens themselves. What’s more, this new approach may be able to cut development costs by more than 30 percent and accelerate timelines by at least 10 percent, while still maintaining high quality and compliance.

The cloud-based model is also helping pharma companies:

  • Focus on the science—rather than the operations—of clinical trial execution.
  • Facilitate data exchange between external partners. We’re already seeing this with TransCelerate Biopharma, a nonprofit joint venture which brings together 10 Big Pharma companies to find ways to make the clinical trials process more efficient.
  • Establish foundational capabilities to facilitate future growth and efficiency.

For most pharmaceutical companies constrained by the costs of drug development, regulations and lengthy timelines, this change in approach couldn’t come soon enough. Far-sighted pharmas know they need to overhaul their approach to R&D. Pre-competitive collaboration could be that sharp turn that puts them back on the road to profitable growth and helps them rethink, reshape and restructure for better patient outcomes.

To learn more, download: Pharma’s Sharp Right Turn on R&D: Creating an IT Platform to Fuel Future Growth.


Comment Form

CAPTCHA code image
Speak the codeChange the code

Please type in the characters displayed above.

* Please note that your name and email address are required
  to submit a comment. Your email will not be published.
About the Authors
Anne O'Riordan
Anne O'Riordan is a Senior Managing Director responsible for Accenture's Global Life Sciences Practice. Worked throughout Europe, th...
Andrea Brueckner
Andrea Brueckner is a Managing Director in Accenture’s Life Sciences practice. She also leads the practice in Europe, Africa and Lat...
Doug Mowen
Doug Mowen is a Managing Director for Accenture’s Medical Technology Practice. With 25 years of experience and 15 years serving the ...
James Crowley is a Managing Director and Life Sciences Lead within Accenture Strategy. In his current role he focuses on helping C-s...
Jeff Elton
Jeff Elton is a Managing Director of Accenture Life Sciences, with broad responsibilities for the strategy and partnerships f...
Kevin Julian
Kevin Julian is a Managing Director and Global Lead for Accenture's Life Sciences Accelerated R&D Services. Previously he was re...
Shawn Roman
Shawn Roman is a Managing Director in Accenture Life Sciences and leads the North America Commercial Services practice. Mr. Roman ha...
Tom Schwenger
Tom Schwenger is a Senior Managing Director and the Life Sciences North America Client Service Group Lead. In this role, Tom is resp...


By using this site you agree that we can place cookies on your device. See our privacy statement for details.